Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. December 24 ...
The apex court has been hearing a petition filed by Daiichi Sankyo alleging the non-payment of ₹35 billion. The amount had been awarded to the Japanese firm in a previous arbitration in mid-2016 ...
Seeking Alpha on MSN18d
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatmentDaiichi Sankyo and AstraZeneca ( NASDAQ: AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or ...
Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback